Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
with chemotherapy for previously treated EGFR-mutated non-squamous non-small cell lung cancer, supported by Phase III HARMONi trial data and multiple ongoing global studies. Alongside this regulatory push, a broad clinical collaboration around ivonescimab and its expansion into colorectal and other solid tumors highlights Summit's ambition to build a multi-indication oncology franchise. We'll now examine how the ivonescimab BLA submission, and its potential to broaden Summit's oncology footprint, shapes the investment narrative. Uncover the next big thing with financially sound penny stocks that balance risk and reward For Summit, everything now revolves around ivonescimab. To be comfortable as a shareholder, you have to believe this first-in-class antibody can turn today's US$0 revenue base and very large annual losses into a sustainable oncology business. The freshly submitted BLA for EGFR-mutated NSCLC is the key near term catalyst, and it meaningfully sharpens the story: r
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics (NASDAQ:SMMT) was given a new $40.00 price target on by analysts at Piper Sandler.MarketBeat
- Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge [Yahoo! Finance]Yahoo! Finance
- 2 Biotech Stocks That Could Soar This Year [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) [Yahoo! Finance]Yahoo! Finance
SMMT
Earnings
- 10/20/25 - Beat
SMMT
Sec Filings
- 1/12/26 - Form 4
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- SMMT's page on the SEC website